Previous 10 | Next 10 |
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. He...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Plus Therapeutics, Inc. Enters Commercial Manufacturing Supply Agreement with RadioMedix ” Plus Therapeutics, Inc. (NASDAQ: PSTV) climbed 18% in prema...
Plus Therapeutics (NASDAQ:PSTV) +22% on manufacturing deal for Rhenium-186 NanoLiposome Innate Pharma (NASDAQ:IPHA) +17% Monalizumab and ANKET™ data will be presented at ESMO 2021 virtual Congress ChargePoint Holdings (NYSE:CHPT) +16% on Q2 earnings. Tiziana Life Science...
RadioMedix, Inc. is a key manufacturer and supplier of cGMP radiotherapeutics for late-stage clinical trials and commercial production RadioMedix will produce cGMP drug product for Rhenium-186 NanoLiposome ( 186 RNL) and may extend to future products ...
Trillium Therapeutics (NASDAQ:TRIL) +191% after acquisition by Pfizer for $2.3B Vivos Therapeutics (NASDAQ:VVOS) +61% on FDA 510k clearance for sleep apnea treatment device Xeris Pharmaceuticals (NASDAQ:XERS) +48% announces approval of supplemental new drug Application (sN...
Data shows that the administration of Rhenium-186 NanoLiposome ( 186 RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy than with standard modalities Company and academic collaborators outl...
Positive data to support FDA IND application for the clinical evaluation of Rhenium-186 Nanoliposome ( 186 RNL) targeted radiotherapy for patients with leptomeningeal metastases (LM) Presentation outlines plans for Phase 1 dose escalation clinical trial of 186 ...
AUSTIN, Texas, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will present data on ...
Gainers: AeroCentury (NYSE:ACY) +38%. Dyadic International DYAI +31%. CohBar CWBR +24%. TaskUs TASK +21%. Plus Therapeutics (NASDAQ:PSTV) +20%. Doximity DOCS +19%. Upstart Holdings UPST +19%. CuriosityStream CURI +17%. Allied Healthcare Products AHPI +15%. M...
AUSTIN, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult to treat cancers, today announced it will present data fro...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...